Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy

Roberto M. Lemoli, Giovanni Martinelli, Elena Zamagni, Maria Rosa Motta, Simonetta Rizzi, Carolina Terragna, Roberto Rondelli, Sonia Ronconi, Antonio Curti, Francesca Bonifazi, Sante Tura, Michele Cavo

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. Conditioning regimens consisted of high-dose melphalan (MEL) with or without total body irradiation (TX1 = 35) and MEL as the first preparative regimen, followed within 6 months by busulfan and melphalan (TX2 = 47). On the basis of adequate stem cell harvest, 31 patients (TX1 = 13; TX2 = 18) were transplanted with highly purified CD34+ cells. Positively selected stem cells did not adversely affect hematopoietic reconstitution compared with unmanipulated peripheral blood stem cell. Overall, the complete remission (CR) rate of evaluative patients was 13.8% and 41% for single and double autotransplant, respectively (P = .04). Moreover, 3 patients undergoing TX2 achieved molecular remission and 2 remain PCR-negative after 36 and 24 months from autograft. The median event-free survival (EFS) durations for TX1 and TX2 were 17 and 35 months, respectively (P = .03). Actuarial 3-year overall survival for patients treated with 1 or 2 transplants are 76% and 92%, respectively (P = NS). On multivariate analysis, superior EFS was associated with low β2 microglobulin (β2-M) level at diagnosis and TX2, whereas overall survival was correlated with β2-M. Positive selection of CD34+ cells did not influence the achievement of clinical or molecular CR, as well as remission duration or survival of MM patients. Thus, whereas multiple cycles of high-dose therapy may be beneficial for patients with myeloma, the clinical impact of tumor cell purging remains highly questionable. (C) 2000 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)2234-2239
Number of pages6
JournalBlood
Volume95
Issue number7
Publication statusPublished - Apr 1 2000

Fingerprint

Chemotherapy
Stem cells
Multiple Myeloma
Melphalan
Drug Therapy
Autografts
Stem Cells
Purging
Busulfan
Transplants
Disease-Free Survival
Survival
Tumors
Blood
Cells
Irradiation
Whole-Body Irradiation
Multivariate Analysis
Polymerase Chain Reaction
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. / Lemoli, Roberto M.; Martinelli, Giovanni; Zamagni, Elena; Motta, Maria Rosa; Rizzi, Simonetta; Terragna, Carolina; Rondelli, Roberto; Ronconi, Sonia; Curti, Antonio; Bonifazi, Francesca; Tura, Sante; Cavo, Michele.

In: Blood, Vol. 95, No. 7, 01.04.2000, p. 2234-2239.

Research output: Contribution to journalArticle

Lemoli, RM, Martinelli, G, Zamagni, E, Motta, MR, Rizzi, S, Terragna, C, Rondelli, R, Ronconi, S, Curti, A, Bonifazi, F, Tura, S & Cavo, M 2000, 'Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy', Blood, vol. 95, no. 7, pp. 2234-2239.
Lemoli, Roberto M. ; Martinelli, Giovanni ; Zamagni, Elena ; Motta, Maria Rosa ; Rizzi, Simonetta ; Terragna, Carolina ; Rondelli, Roberto ; Ronconi, Sonia ; Curti, Antonio ; Bonifazi, Francesca ; Tura, Sante ; Cavo, Michele. / Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. In: Blood. 2000 ; Vol. 95, No. 7. pp. 2234-2239.
@article{77a3bcbef3ad41cc93ae1d8c974199d7,
title = "Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy",
abstract = "Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. Conditioning regimens consisted of high-dose melphalan (MEL) with or without total body irradiation (TX1 = 35) and MEL as the first preparative regimen, followed within 6 months by busulfan and melphalan (TX2 = 47). On the basis of adequate stem cell harvest, 31 patients (TX1 = 13; TX2 = 18) were transplanted with highly purified CD34+ cells. Positively selected stem cells did not adversely affect hematopoietic reconstitution compared with unmanipulated peripheral blood stem cell. Overall, the complete remission (CR) rate of evaluative patients was 13.8{\%} and 41{\%} for single and double autotransplant, respectively (P = .04). Moreover, 3 patients undergoing TX2 achieved molecular remission and 2 remain PCR-negative after 36 and 24 months from autograft. The median event-free survival (EFS) durations for TX1 and TX2 were 17 and 35 months, respectively (P = .03). Actuarial 3-year overall survival for patients treated with 1 or 2 transplants are 76{\%} and 92{\%}, respectively (P = NS). On multivariate analysis, superior EFS was associated with low β2 microglobulin (β2-M) level at diagnosis and TX2, whereas overall survival was correlated with β2-M. Positive selection of CD34+ cells did not influence the achievement of clinical or molecular CR, as well as remission duration or survival of MM patients. Thus, whereas multiple cycles of high-dose therapy may be beneficial for patients with myeloma, the clinical impact of tumor cell purging remains highly questionable. (C) 2000 by The American Society of Hematology.",
author = "Lemoli, {Roberto M.} and Giovanni Martinelli and Elena Zamagni and Motta, {Maria Rosa} and Simonetta Rizzi and Carolina Terragna and Roberto Rondelli and Sonia Ronconi and Antonio Curti and Francesca Bonifazi and Sante Tura and Michele Cavo",
year = "2000",
month = "4",
day = "1",
language = "English",
volume = "95",
pages = "2234--2239",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy

AU - Lemoli, Roberto M.

AU - Martinelli, Giovanni

AU - Zamagni, Elena

AU - Motta, Maria Rosa

AU - Rizzi, Simonetta

AU - Terragna, Carolina

AU - Rondelli, Roberto

AU - Ronconi, Sonia

AU - Curti, Antonio

AU - Bonifazi, Francesca

AU - Tura, Sante

AU - Cavo, Michele

PY - 2000/4/1

Y1 - 2000/4/1

N2 - Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. Conditioning regimens consisted of high-dose melphalan (MEL) with or without total body irradiation (TX1 = 35) and MEL as the first preparative regimen, followed within 6 months by busulfan and melphalan (TX2 = 47). On the basis of adequate stem cell harvest, 31 patients (TX1 = 13; TX2 = 18) were transplanted with highly purified CD34+ cells. Positively selected stem cells did not adversely affect hematopoietic reconstitution compared with unmanipulated peripheral blood stem cell. Overall, the complete remission (CR) rate of evaluative patients was 13.8% and 41% for single and double autotransplant, respectively (P = .04). Moreover, 3 patients undergoing TX2 achieved molecular remission and 2 remain PCR-negative after 36 and 24 months from autograft. The median event-free survival (EFS) durations for TX1 and TX2 were 17 and 35 months, respectively (P = .03). Actuarial 3-year overall survival for patients treated with 1 or 2 transplants are 76% and 92%, respectively (P = NS). On multivariate analysis, superior EFS was associated with low β2 microglobulin (β2-M) level at diagnosis and TX2, whereas overall survival was correlated with β2-M. Positive selection of CD34+ cells did not influence the achievement of clinical or molecular CR, as well as remission duration or survival of MM patients. Thus, whereas multiple cycles of high-dose therapy may be beneficial for patients with myeloma, the clinical impact of tumor cell purging remains highly questionable. (C) 2000 by The American Society of Hematology.

AB - Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. Conditioning regimens consisted of high-dose melphalan (MEL) with or without total body irradiation (TX1 = 35) and MEL as the first preparative regimen, followed within 6 months by busulfan and melphalan (TX2 = 47). On the basis of adequate stem cell harvest, 31 patients (TX1 = 13; TX2 = 18) were transplanted with highly purified CD34+ cells. Positively selected stem cells did not adversely affect hematopoietic reconstitution compared with unmanipulated peripheral blood stem cell. Overall, the complete remission (CR) rate of evaluative patients was 13.8% and 41% for single and double autotransplant, respectively (P = .04). Moreover, 3 patients undergoing TX2 achieved molecular remission and 2 remain PCR-negative after 36 and 24 months from autograft. The median event-free survival (EFS) durations for TX1 and TX2 were 17 and 35 months, respectively (P = .03). Actuarial 3-year overall survival for patients treated with 1 or 2 transplants are 76% and 92%, respectively (P = NS). On multivariate analysis, superior EFS was associated with low β2 microglobulin (β2-M) level at diagnosis and TX2, whereas overall survival was correlated with β2-M. Positive selection of CD34+ cells did not influence the achievement of clinical or molecular CR, as well as remission duration or survival of MM patients. Thus, whereas multiple cycles of high-dose therapy may be beneficial for patients with myeloma, the clinical impact of tumor cell purging remains highly questionable. (C) 2000 by The American Society of Hematology.

UR - http://www.scopus.com/inward/record.url?scp=12944260585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944260585&partnerID=8YFLogxK

M3 - Article

C2 - 10733490

AN - SCOPUS:12944260585

VL - 95

SP - 2234

EP - 2239

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -